Next-generation gene promoters for more stable and higher recombinant protein expression.

Pionering whole genome sequencing based genotoxicity testing

GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score (MVHS)

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.

HELIA Biomonitoring’s mission is to enable continuous monitoring of therapeutic drug concentrations, organ function markers, and treatment response markers for personalized patient care.

the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

Injectable bone filler with drug release function for treatment of bone infections (INBORN)